Christina Smolke, Sang Yup Lee, Jens Nielsen, Gregory Stephanopoulos, Christina Smolke
This is a test
This is a test
Share book
English
ePUB (mobile friendly)
Available on iOS & Android
eBook - ePub
Synthetic Biology
Parts, Devices and Applications
Christina Smolke, Sang Yup Lee, Jens Nielsen, Gregory Stephanopoulos, Christina Smolke
Book details
Book preview
Table of contents
Citations
About This Book
A review of the interdisciplinary field of synthetic biology, from genome design to spatial engineering.
Written by an international panel of experts, Synthetic Biology draws from various areas of research in biology and engineering and explores the current applications to provide an authoritative overview of this burgeoning field. The text reviews the synthesis of DNA and genome engineering and offers a discussion of the parts and devices that control protein expression and activity. The authors include information on the devices that support spatial engineering, RNA switches and explore the early applications of synthetic biology in protein synthesis, generation of pathway libraries, and immunotherapy.
Filled with the most recent research, compelling discussions, and unique perspectives, Synthetic Biology offers an important resource for understanding how this new branch of science can improve on applications for industry or biological research.
Frequently asked questions
How do I cancel my subscription?
Simply head over to the account section in settings and click on āCancel Subscriptionā - itās as simple as that. After you cancel, your membership will stay active for the remainder of the time youāve paid for. Learn more here.
Can/how do I download books?
At the moment all of our mobile-responsive ePub books are available to download via the app. Most of our PDFs are also available to download and we're working on making the final remaining ones downloadable now. Learn more here.
What is the difference between the pricing plans?
Both plans give you full access to the library and all of Perlegoās features. The only differences are the price and subscription period: With the annual plan youāll save around 30% compared to 12 months on the monthly plan.
What is Perlego?
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, weāve got you covered! Learn more here.
Do you support text-to-speech?
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Is Synthetic Biology an online PDF/ePUB?
Yes, you can access Synthetic Biology by Christina Smolke, Sang Yup Lee, Jens Nielsen, Gregory Stephanopoulos, Christina Smolke in PDF and/or ePUB format, as well as other popular books in Biological Sciences & Biotechnology. We have over one million books available in our catalogue for you to explore.
Chapter 1 Competition and the Future of Reading and Writing DNA
Robert Carlson
Biodesic and Bioeconomy Capital, 3417 Evanston Ave N, Ste 329, Seattle, WA, 98103, USA
Constructing arbitrary genetic instruction sets is a core technology for biological engineering. Biologists and engineers are pursuing even better methods to assemble these arbitrary sequences from synthetic oligonucleotides (oligos) [1]. These new assembly methods in principle reduce costs, improve access, and result in long sequences of errorāfree DNA that can be used to construct entire microbial genomes [2]. However, an increasing diversity of assembly methods is not matched by any obvious corresponding innovation in producing oligos. Commercial oligo production employs a very narrow technology base that is many decades old. Consequently, there is only minimal price and product differentiation among corporations that produce oligos. Prices have stagnated, which in turn limits the economic potential of new assembly methods that rely on oligos. Improvements may come via recently demonstrated assembly methods that are capable of using oligos of lower quality and lower cost as feedstocks. However, while these new methods may substantially lower the cost of geneālength doubleāstranded DNA (dsDNA), they also may be economically viable only when producing many orders of magnitude with more dsDNA than what is now used by the market. The commercial success of these methods, and the broader access to dsDNA they enable, may therefore depend on structural changes in the market that are yet to emerge.
1.1 Productivity Improvements in Biological Technologies
In considering the larger impact of technological monoculture in DNA synthesis, it is useful to contrast DNA synthesis and assembly with DNA sequencing. In particular, it is instructive to compare productivity estimates of commercially available sequencing and synthesis instruments (Figure 1.1). Reading DNA is as crucial as writing DNA to the future of biological engineering. Due to not just commercial competition but also competition between sequencing technologies, both prices and instrument capabilities are improving rapidly. The technological diversity responsible for these improvements poses challenges in making quantitative comparisons. As in previous discussions of these trends, in what follows I rely on the metrics of price [$/base] and productivity [bases/person/day].
Figure 1.1 also directly compares the productivity enabled by commercially available sequencing and synthesis instruments to Mooreās law, which describes the exponential increase in transistor counts in CPUs over time. Readers new to this discussion are referred to References 3 and 4 for inādepth descriptions of the development of these metrics and the utility of a comparison with Mooreās law [3, 7]. Very briefly, Mooreās law is a proxy for productivity; more transistors enable greater computational capability, which putatively equates to greater productivity.
Visual inspection of Figure 1.1 reveals several interesting features. First, general synthesis productivity has not improved for several years because no new instruments have been released publicly since about 2008. Productivity estimates for instruments developed and run by oligo and gene synthesis service providers are not publicly available.1
Second, it is clear that DNA sequencing platforms are improving very rapidly, now much faster than Mooreās law.
Mooreās law and its economic and social consequences are often used to benchmark our expectations of other technologies. Therefore, developing an understanding of this ālawā provides a means to compare and contrast it with other technological trends.
1.2 The Origin of Mooreās Law and Its Implications for Biological Technologies
Mooreās law is often mistakenly described as a technological inevitability or is assumed to be some sort of physical phenomenon. It is neither; Mooreās law is a business plan, and as such it is based on economics and planning. Gordon Mooreās somewhat opaque original statement of what became the ālawā was a prediction concerning economically viable transistor yields [8]. Over time, Mooreās economic observation became an operational model based on monopoly pricing, and it eventually enabled Intel to outcompete all other manufacturers of general CPUs. Two important features distinguish CPUs from other technologies and provide insight into the future of trends in biological technologies: the first is the cost of production, and the second is the monopoly pricing structure.
Early on Intel recognized the utility of exploiting Mooreās law as a business plan. A simple scaling argument reveals the details of the plan. While transistor counts increased exponentially, Intel correspondingly reduced the price per transistor at a similar rate. In order to maintain revenues, the company needed to ship proportionally more transistors every quarter; in fact, the company increased its shipping numbers faster than prices fell, enabling consistent revenue to grow for several decades. This explains why Intel former CEO Andy Grove reportedly constantly pushed for an even greater scale [9].
In this sense, Mooreās law was always about economics and planning in a multibillionādollar industry. In the year 2000, a new chip fab cost about $1 billion; in 2009, it cost about $3 billion. Now, according to The Economist, Intel estimates that a new chip fab costs about $10 billion [9]. This apparent exponential increase in the cost of semiconductor processing is known as Rockās law. It is often argued that Mooreās law will eventually expire due to the physical constraints of fabricating transistors at small length scales, but it is more likely to become difficult to economically justify constructing fabrication facilities at the cost of tens to hundreds of billions of dollars. Even through the next several iterations, these construction costs will dictate careful planning that spans many years. No business spends $10 billion without a great deal of planning, and, more directly, no business finances a manufacturing plant that expensive without demonstrating a longāterm plan to repay the financiers. Moreover, Intel must coordinate the manufacturing and delivery of very expensive, very complex semiconductor processing instruments made by other companies. Thus Intelās planning and finance cycles explicitly extend many years into the future. New technology has certainly been required to achieve each planning goal, but this is part of the ongoing research, development, and planning process for Intel.